Ultrasensitive Measurement of Protein and Acid Biomarkers for Earlier Disease Detection and More Effective Therapies

摘要

It is a universal fact substantiated. decades of biopharmaceutical research: the earlier a disease is detected, the more likely treatments will be effective in alleviating or stabilizing the disease process. As a result, the need for earlier diagnosisto help ensure positive outcomes has become central to the mindsets of researchers, clinicians, patients, and third-party payers. The pharmaceutical industry is striving to develop effective new therapies for diseases, ranging from cancers to cardiovascular and neurodegenerative disorders to a host of metabolic, infectious, and genetic conditions, and is placing emphasis on treatments related to the early detection of disease. The development of new molecular diagnostic methods capable of detecting disease at the molecular level in blood, cerebrospinal fluid, and other body specimens lies at the core of an emerging revolution in disease diagnosis. Using specific and targeted protein and nucleic acid (i.e., DNA and RNA) biomarkers, clinicians will be able to detect diseases and confirm diagnoses very early on. Ideally, clinicians may be able to diagnose even before patients present with clinical signs and symptoms—when a disease is most amenable to successful treatment.